Christopher M. Cashman
About Christopher M. Cashman
Christopher M. Cashman is a seasoned director with over four decades of experience in biopharmaceuticals, focusing on neuropsychiatric, epilepsy, and antibacterial therapeutics. He currently holds leadership positions at MBF Therapeutics Inc. and Telesis Therapeutics, among others, and has a strong background in translating scientific advancements into health solutions.
Work at Noble Biomaterials
Christopher M. Cashman has served as Director at Noble Biomaterials since 2010. In this role, he contributes to the company's mission of developing innovative materials and technologies. His leadership focuses on translating scientific advancements into practical applications, particularly in health solutions. Noble Biomaterials specializes in antimicrobial technologies and advanced materials, which align with Cashman's extensive background in therapeutics.
Current Positions at MBF Therapeutics Inc. and Telesis Therapeutics
Since 2008, Cashman has held the position of Chairman at MBF Therapeutics Inc., where he has been instrumental in guiding the company's strategic direction. In addition, he has been serving as Director at Telesis Therapeutics since 2021. His involvement in these organizations highlights his commitment to advancing therapeutic solutions in the biopharmaceutical sector.
Education and Expertise
Christopher M. Cashman earned a Bachelor of Science in Business Administration and Management from the University of Minnesota, studying from 1974 to 1978. He furthered his education at Purdue University, obtaining a Master of Science in Economics from 1978 to 1980. His academic background complements his extensive experience in the biopharmaceutical industry, particularly in the development and commercialization of therapeutics.
Background in Biopharmaceuticals
Cashman has over four decades of experience in senior executive roles within early and mid-stage biopharmaceutical companies and major divisions of large pharmaceutical firms. His career includes significant positions such as President of Protez Pharmaceuticals at Novartis and Chairman and CEO of Marinus Pharma. His expertise encompasses the development of neuropsychiatric, epilepsy, and antibacterial therapeutics, as well as animal health biologics.
Previous Leadership Roles
Throughout his career, Christopher M. Cashman has held various leadership roles that demonstrate his expertise in the biopharmaceutical industry. He served as Chairman at JDP Therapeutics Inc. from 2009 to 2019 and as Director at PolyCore Therapeutics LLC from 2021 to 2023. These positions reflect his ongoing commitment to advancing health solutions through innovative therapeutic development.